ASX:TLX Telix Pharmaceuticals (TLX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Telix Pharmaceuticals Stock (ASX:TLX) 30 days 90 days 365 days Advanced Chart Get Telix Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume746,789 shsAverage VolumeN/AMarket CapitalizationA$9.14 billionP/E Ratio290.42Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its products portfolio include Illuccix for the treatment of prostate cancer;, TLX591, a radio antibody-drug conjugate, which is in phase 3 clinical trial for the treatment of prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX599-CDx for treatment of prostate cancer imaging agent. The company was founded in 2015 and is headquartered in North Melbourne, Australia. Read More Receive TLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TLX Stock News HeadlinesTLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with ...August 25 at 4:30 AM | gurufocus.comWhy Telix shares could rocket 60%+August 22, 2025 | msn.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.August 26 at 2:00 AM | American Alternative (Ad)Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLXAugust 22, 2025 | tmcnet.comTelix Pharmaceuticals Limited: Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growthAugust 21, 2025 | finanznachrichten.deFDA Waiting Room: For Aussie applicants, it’s (mainly) business as usualAugust 11, 2025 | msn.comDr Boreham’s Crucible: Telix has homework but remains dux of radioimaging classAugust 5, 2025 | msn.comWhy did the Telix share price just plunge 18%?August 5, 2025 | msn.comSee More Headlines TLX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Telix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Telix Pharmaceuticals investors own include bluebird bio (BLUE), Atara Biotherapeutics (ATRA), Esperion Therapeutics (ESPR), Forte Biosciences (FBRX), Faraday Future Intelligent Electric (FFIE), Abbott Laboratories (ABT) and ADMA Biologics (ADMA). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:TLX CIKN/A Webwww.telixpharma.com Phone61 4 4914 8448FaxN/AEmployees234Year FoundedN/AProfitability EPS (Trailing Twelve Months)A$0.15 Trailing P/E Ratio290.42 Forward P/E RatioN/A P/E GrowthN/ANet IncomeA$49.19 million Net Margins6.63% Pretax MarginN/A Return on Equity11.29% Return on Assets7.97% Debt Debt-to-Equity Ratio5.48 Current Ratio0.99 Quick Ratio3.00 Sales & Book Value Annual SalesA$645.68 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow8.35 Book ValueA$1.21 per share Price / BookN/AMiscellaneous Outstanding Shares334,680,000Free FloatN/AMarket CapA$9.14 billion OptionableNot Optionable Beta2.40 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (ASX:TLX) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telix Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Telix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.